Efficacy Of Fludarabine Combined With Cyclophosohamide For Patients With Chronici Lyphocytic Leukemia

Objective: To evaluate the efficacy of fludarabine combined withcyclophosphamide (FC) regimen for chronic lymphocytic leukemia (CLL).Methods: Clinical data of41patients with CLL treated by FC regimenfrom2008to2013were retrospectively analyzed. Results: The rates ofcomplete response (CR), partial response (PR) and overall response (OR)were41.5%,36.6%and78.1%respectively. There was no differencebetween initial and secondary treatment groups in CR,PR and OR rates(58.8%,23.5%,82.4%vs29.1%,45.8%,75%, P＞0.05). The main sideeffects were myelosuppression and immunologic function suppression andthere was no difference in hematotoxicity between two groups (P＞0.05).There are32patients had finished4cycles of chemotherapy. Thedisease-free survival (DFS) rate of initial treatment group was better thanthat of secondary treatment group (53.6±14.5%vs20.8±9.9%, P＜0.05),but there was no difference in the overall survival (OS) rate between twogroups (77.1±11.7%vs47.3±13.3%, P＞0.05). Conclusions: FC combined chemotherapty regimen can improve the prognosis and disease-freesurvival of patients with CLL. It is the currently preferred scheme forpatients with CLL due to its good efficacy and tolerance, but more attentionshould be paid to the long-term effect.